Recent studies suggest that glycoprotein 130 (Gp130) receptor ligands comprise potential therapeutic targets for obesity;[12, 13] however, the role of Gp130 signaling in insulin resistance remains controversial.[14] Gp130 is the common subunit of the receptor signaling complex for the interleukin‐6 (IL‐6) family of cytokines and is ubiquitously expressed.[14] The effect of Gp130 ligands in metabolic disease is unclear and is likely to be context‐dependent, especially with respect to IL‐6. This evidence concerns the gene IL6 and metabolic disease.